Compare PBF & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBF | EWTX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2011 | 2021 |
| Metric | PBF | EWTX |
|---|---|---|
| Price | $50.02 | $30.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $33.30 | ★ $37.38 |
| AVG Volume (30 Days) | ★ 3.8M | 730.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 69.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,508,200,000.00 | N/A |
| Revenue This Year | $1.73 | N/A |
| Revenue Next Year | $0.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.62 | $10.60 |
| 52 Week High | $50.47 | $31.82 |
| Indicator | PBF | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.28 | 55.34 |
| Support Level | $27.35 | $26.91 |
| Resistance Level | N/A | $31.28 |
| Average True Range (ATR) | 2.83 | 1.48 |
| MACD | 0.52 | -0.01 |
| Stochastic Oscillator | 95.84 | 73.82 |
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines, and storage facilities. The Logistics segment consists solely of PBFX's operations.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.